LLY

738.06

+1.61%↑

JNJ

178.12

-0.03%↓

ABBV

209.99

-1.09%↓

UNH

320.2

+1.63%↑

NVO

54.31

-1.47%↓

LLY

738.06

+1.61%↑

JNJ

178.12

-0.03%↓

ABBV

209.99

-1.09%↓

UNH

320.2

+1.63%↑

NVO

54.31

-1.47%↓

LLY

738.06

+1.61%↑

JNJ

178.12

-0.03%↓

ABBV

209.99

-1.09%↓

UNH

320.2

+1.63%↑

NVO

54.31

-1.47%↓

LLY

738.06

+1.61%↑

JNJ

178.12

-0.03%↓

ABBV

209.99

-1.09%↓

UNH

320.2

+1.63%↑

NVO

54.31

-1.47%↓

LLY

738.06

+1.61%↑

JNJ

178.12

-0.03%↓

ABBV

209.99

-1.09%↓

UNH

320.2

+1.63%↑

NVO

54.31

-1.47%↓

Search

Crinetics Pharmaceuticals Inc

Отворен

СекторЗдравеопазване

35.26 1.12

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

34.61

Максимум

35.75

Ключови измерители

By Trading Economics

Приходи

-19M

-116M

Продажби

670K

1M

Марж на печалбата

-11,216.004

Служители

437

EBITDA

-19M

-129M

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+99.63% upside

Дивиденти

By Dow Jones

Следващи печалби

11.11.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

275M

2.9B

Предишно отваряне

34.14

Предишно затваряне

35.26

Настроения в новините

By Acuity

4%

96%

2 / 371 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Weak Bullish Evidence

Crinetics Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

8.09.2025 г., 23:59 ч. UTC

Придобивния, сливания и поглъщания

Anglo American Is in Talks to Buy Teck Resources, Bloomberg Says

8.09.2025 г., 22:02 ч. UTC

Значими двигатели на пазара

Microsoft Signs $17.4 Billion AI Deal With Nebius

8.09.2025 г., 17:01 ч. UTC

Значими двигатели на пазара

Eightco Holdings Stock Surges as Dan Ives Joins Board Amid Crypto Push

8.09.2025 г., 17:01 ч. UTC

Значими двигатели на пазара

Tron Shares Rise After New Investment From Bravemorning

8.09.2025 г., 16:14 ч. UTC

Значими двигатели на пазара

Beyond Air Shares Climb on FDA Orphan Drug Designation for Brain Cancer Treatment

8.09.2025 г., 16:13 ч. UTC

Значими двигатели на пазара

Dianthus Shares Whipsaw on Strong Trial Results, Safety Concerns

8.09.2025 г., 23:12 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

8.09.2025 г., 23:12 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

8.09.2025 г., 23:12 ч. UTC

Пазарно говорене

Infratil's New Bull Likes Exposure to Growing Infrastructure Businesses -- Market Talk

8.09.2025 г., 22:56 ч. UTC

Пазарно говорене

Worst May Be Over for New Zealand Retailers -- Market Talk

8.09.2025 г., 22:23 ч. UTC

Пазарно говорене

Ebos's Near-Term Earnings Outlook Dims -- Market Talk

8.09.2025 г., 21:51 ч. UTC

Пазарно говорене

AT&T Backs Outlook After EchoStar Spectrum Purchase -- Market Talk

8.09.2025 г., 21:47 ч. UTC

Значими двигатели на пазара

Microsoft Signs $17.4B AI Deal With Nebius

8.09.2025 г., 21:33 ч. UTC

Придобивния, сливания и поглъщания

This Quantum Pure Play Is Going Public. What Infleqtion Does Differently, Says Its CEO. -- Barrons.com

8.09.2025 г., 21:20 ч. UTC

Придобивния, сливания и поглъщания

MEG Energy Plans to Respond on or Before Sept 15 >MEG.T

8.09.2025 г., 21:19 ч. UTC

Придобивния, сливания и поглъщания

MEG Energy Special Committee and Board Will Evaluate Revised Strathcona Offer >MEG.T

8.09.2025 г., 21:18 ч. UTC

Придобивния, сливания и поглъщания

MEG Energy Acknowledges Strathcona's Intention to Revise Offer

8.09.2025 г., 20:50 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

Tech, Media & Telecom Roundup: Market Talk

8.09.2025 г., 19:33 ч. UTC

Пазарно говорене

Oil Futures Gain Despite Planned OPEC+ Output Increases -- Market Talk

8.09.2025 г., 19:22 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Settle Higher -- Market Talk

8.09.2025 г., 19:02 ч. UTC

Пазарно говорене

Dollar Lukewarm Amid Data Hiatus Ahead of August CPI -- Market Talk

8.09.2025 г., 18:24 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

8.09.2025 г., 18:24 ч. UTC

Пазарно говорене

Weaker Argentine Peso Profitable for Grain Producers -- Market Talk

8.09.2025 г., 17:29 ч. UTC

Пазарно говорене

Mexican Inflation Seen Little Changed in August -- Market Talk

8.09.2025 г., 16:59 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

SpaceX Spectrum Acquisition Will Create More Satellite Connection Supply, Verizon CEO Says -- Market Talk

8.09.2025 г., 16:36 ч. UTC

Пазарно говорене

Crude Futures Hold Gains After OPEC+ Output Decision -- Market Talk

8.09.2025 г., 16:20 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

8.09.2025 г., 16:16 ч. UTC

Печалби

Strategy Stock May Not Ever Make It Into the S&P 500 Index -- Barrons.com

8.09.2025 г., 16:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

8.09.2025 г., 16:04 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

Сравнение с други в отрасъла

Ценова промяна

Crinetics Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

99.63% нагоре

12-месечна прогноза

Среден 71.09 USD  99.63%

Висок 97 USD

Нисък 36 USD

Според 12 анализатори от Wall Street, предложили 12-месечна ценова цел за Crinetics Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

12 ratings

11

Купи

1

Задържане

0

Продай

Техническа оценка

By Trading Central

30.39 / 33.46Подкрепа & съпротива

Краткосрочен план

Weak Bullish Evidence

Средносрочен план

Bearish Evidence

Дългосрочен план

Neutral Evidence

Настроение

By Acuity

2 / 371 Класиране в Здравеопазване

Настроения в новините

Много силни бичи доказателства

Волатилност

Под средното

Обем новини (RCV)

Над средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
help-icon Live chat